Collegium Pharmaceutical completed the acquisition of BioDelivery Sciences International for $604m.

Collegium Pharmaceutical, a pharmaceutical company, completed the acquisition of BioDelivery Sciences International, a pharmaceutical company, for $604m. “This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. We have significantly diversified the business and expanded our overall revenue scale. This transaction is immediately and highly accretive, and we are now focused on seamless integration and delivering identified synergies of at least $75m within twelve months," Joe Ciaffoni, Collegium President and CEO.